Changes in American policy mean cancer canadian children lose access to clinical trials
Canadian researchers say they had to stop offering children with cancer places in some clinical trials due to funds and policy changes in the United States.
The US government is preventing funds for some pediatric clinical trials outside the US, and does not renew funds for pediatric brain tumor consortium, a network of experts that perform clinical testing and focus on improving treatment for brain tumors.
The only Canadian site in the network is at the Sick Kids Hospital in Toronto.
The President of the C17 Council, representing Canada’s pediatric cancer programs, Dr. The Division Head of Hematology/Oncology in Jim WHILOLD, and Sick Kids said that he had to stop enrollment of new patients in three clinical trials due to change. Current patients can continue to receive treatment.
The US government is not renewing funding for the pediatric brain tumor consortium, a network of experts focusing on improving treatment for brain tumors, and the Psychids Hospital in Toronto has to stop enrollment of children in some new tests as a result.
“These are the most promising treatment for children with special diseases, and not really a study of equivalent promises that we have access.”
US National Institute of Health, Agency, responsible, said that the work of the consortium will go to another network with sites in Canada – but is facing a freeze on funding for trials outside the US.
The network, the pediatric initial stage clinical testing network (PEP-CN), has two Canadian sites, one in sick children and the other in Chu Santa-Justin Children’s Hospital in Montreal.
“This change is worrying,” Dr. Pep-CTN Medical Director Dr. in Canada. Thai Hoa Tran said, and a pediatric oncologist in Stei-Jestin.
Tran says two Canadian clinical trials for pediatric cancer have stopped enrolling patients due to freeze.
“The message that we have received is that nomination for Canadian children has stopped.”
In a statement by CBC News, PEP-CTN Chair Elizabeth Fox said that the network learned in August that its overall funding would continue, was on funding hold for non-US sites and the nomination of new patients outside the US was stopped.
Clinical trials may be the final option
Childhood cancer is rare, with about 1,000 children under 15 years of age Diagnosis in Canada Every year. While most of the treatment reacts well for treatment, not all do. In those cases, the clinical trial may be a final option, a pediatric neurosurgeon at McMaster University. Sheila Singh says.
“Many times with pediatric brain cancer, we come to a point where it is no longer treatable by standard therapeutic methods and the only hope for these children is looking for an experimental therapy,” he said.
Clinical trials are the most difficult-to-healing cases, so the number of affected children is small, but lion says that losing access to tests still represents a major loss for potential patients and for future research.
“We had recently two patients who had barely treated, treatment-deserted brain cancer that could be eligible for one of those tests,” he said.
“But now those tests have been discontinued, and so we cannot offer those expectation and promising experimental medical options.”
Patient’s perspective
When it comes to cases of pediatric cancer, no decision is easy for the parents, the Chairman of the Keith McIntosh, AC2 OR, says a advocacy group for families of children with cancer.
When McIntosh’s son was detected brain cancer at the age of nine, he had surgery, proton radiation and chemotherapy. He is now 17 years old and is ready to graduate in high school in Ottawa.
After treatment, he also participated in a clinical trial, testing a drug to help heal the brain.
Mcintosh says that he worries other children about losing access to similar opportunities.
“Losing any option that provides opportunities for treatment or for a meaningful benefit … can be disastrous,” he said.
The parents of three-year-old Emet Dulan came to know that he had an aggressive brain tumor a few days after his birth.
She started chemotherapy at the age of three weeks and soon joined a clinical trial at BC Children’s Hospital, targeting her specific types of tumors. The oral administration of the drug allowed him to treat the house of Kitamat village in his house.
“This is the best thing that ever happened to him,” said Emmet’s mother, Leena Dolan.
“With all the harsh side effects with Chemo, I don’t think she would have lasted for this long,” she said.
Canada should promote capacity
Given the ongoing funding and policy changes in American health care under the Trump administration, researchers say Canada should promote its ability to do more clinical testing here.
A cardiologist and Professor of McMaster University, Dr. PJ Devero said, “We need our federal government that they are interrupting skilled clinical test conduct in Canada.”
“We are a very complex and expensive place to conduct research,” said Kathy Broadur-Robb, Executive Director of C17 Council.
She says that this country needs to be brought in a position to become less dependent on America.
“Canada needs to get its work simultaneously.”
“With recent funding and policy changes in the United States, the research has been a difficult and unstable time for the research community,” and said that it is working to assess the full impact of changes.
NIH said that it will work for Canadian institutions to find ways to enroll in clinical trials in future, once the infection is complete.
